hBD-1 vs Ziconotide
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and Ziconotide (ω-Conotoxin MVIIA (ziconotide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hBD-1 | Ziconotide |
|---|---|---|
| Category | Dental & Oral | Pain Management |
| Full Name | Human beta-defensin 1 | ω-Conotoxin MVIIA (ziconotide) |
| Molecular Weight | 4490 Da | 2639.1 Da |
| Half-Life | minutes to hours | approximately 4.5 hours |
| Amino Acids | 36 | 25 |
| Typical Dose | 1-10 µg/mL in experimental studies | 0.5-19.2 mcg/day |
| Route | Topical/Intraoral | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 500 |
| Research Status | Pre-clinical | Approved |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.